Pharmaceutical Technology

SEPTEMBER 13, 2022

The company provides strategic assistance and regulatory support to biopharma firms across the lifecycle of the product. On closing of the deal, the results of PharmaLex will be included as a component within the International Healthcare Solutions sector of AmerisourceBergen.

Biopharma 52

Biopharma Manufacturing Pharmaceutical manufacturing Marketing 52

European Pharmaceutical Review

DECEMBER 21, 2022

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.

Manufacturing 97

Manufacturing Pharmaceutical Healthcare Healthcare 97

Clarivate

MARCH 14, 2024

Nitrosamines have garnered significant attention from the pharmaceutical industry due to their detection in commonly prescribed medications for conditions like type 2 diabetes, high blood pressure, and heartburn. [1] Manufacturers, healthcare providers, and consumers alike face the need to quickly adapt.

Pharmaceutical 52

Pharmaceutical Manufacturing Food Healthcare Provider 52

PM360

SEPTEMBER 30, 2024

In late 2023, Deloitte found that over half of 105 surveyed global biopharma leaders were committed to reducing environmental impact and advancing sustainability by minimizing water use, sourcing sustainable materials, and overhauling supply chains.

Manufacturing 52

Manufacturing Pharma Pharmaceutical Competition 52

pharmaphorum

AUGUST 4, 2022

In particular, for the pharmaceutical industry, these talent shortages bring about a host of difficult challenges. This is due to the specialist nature of roles and the growth and diversification of biopharma, which requires an increasingly sophisticated and skilled workforce. Training and development. Raising the profile.

Recruitment 98

Recruitment Training Pharma Pharmaceutical manufacturing 98

Clarivate

AUGUST 20, 2024

In announcing the results of price negotiations between the Centers for Medicare & Medicaid Services (CMS) and pharmaceutical manufacturers, the federal government has demonstrated that it can replicate private payers’ ability to reduce the net price of treatment while focusing on the clinical benefit of a treatment versus therapeutic alternatives (..)

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52